225 related articles for article (PubMed ID: 20003335)
21. Blood-based markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance).
Hatch AJ; Sibley AB; Starr MD; Brady JC; Jiang C; Jia J; Bowers DL; Pang H; Owzar K; Niedzwiecki D; Innocenti F; Venook AP; Hurwitz HI; Nixon AB;
Cancer Med; 2016 Sep; 5(9):2249-60. PubMed ID: 27465221
[TBL] [Abstract][Full Text] [Related]
22. Role of genomic factors beyond thymidylate synthase in the prediction of response to 5-fluorouracil.
Peters GJ; Smid K; Meijer E; van Groeningen CJ; Leon LG
Nucleosides Nucleotides Nucleic Acids; 2016 Dec; 35(10-12):595-603. PubMed ID: 27906628
[TBL] [Abstract][Full Text] [Related]
23. LGR5 and CD133 as prognostic and predictive markers for fluoropyrimidine-based adjuvant chemotherapy in colorectal cancer.
Stanisavljević L; Myklebust MP; Leh S; Dahl O
Acta Oncol; 2016 Dec; 55(12):1425-1433. PubMed ID: 27435662
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of CpG Island Methylator Phenotype as a Biomarker in Colorectal Cancer Treated With Adjuvant Oxaliplatin.
Cohen SA; Wu C; Yu M; Gourgioti G; Wirtz R; Raptou G; Gkakou C; Kotoula V; Pentheroudakis G; Papaxoinis G; Karavasilis V; Pectasides D; Kalogeras KT; Fountzilas G; Grady WM
Clin Colorectal Cancer; 2016 Jun; 15(2):164-9. PubMed ID: 26702772
[TBL] [Abstract][Full Text] [Related]
25. Andrographis overcomes 5-fluorouracil-associated chemoresistance through inhibition of DKK1 in colorectal cancer.
Zhao Y; Wang C; Goel A
Carcinogenesis; 2021 Jun; 42(6):814-825. PubMed ID: 33822896
[TBL] [Abstract][Full Text] [Related]
26. Increased levels of copper efflux transporter ATP7B are associated with poor outcome in colorectal cancer patients receiving oxaliplatin-based chemotherapy.
Martinez-Balibrea E; Martínez-Cardús A; Musulén E; Ginés A; Manzano JL; Aranda E; Plasencia C; Neamati N; Abad A
Int J Cancer; 2009 Jun; 124(12):2905-10. PubMed ID: 19296535
[TBL] [Abstract][Full Text] [Related]
27. Serum miR-19a predicts resistance to FOLFOX chemotherapy in advanced colorectal cancer cases.
Chen Q; Xia HW; Ge XJ; Zhang YC; Tang QL; Bi F
Asian Pac J Cancer Prev; 2013; 14(12):7421-6. PubMed ID: 24460313
[TBL] [Abstract][Full Text] [Related]
28. Reactivating p53 and Inducing Tumor Apoptosis (RITA) Enhances the Response of RITA-Sensitive Colorectal Cancer Cells to Chemotherapeutic Agents 5-Fluorouracil and Oxaliplatin.
Wiegering A; Matthes N; Mühling B; Koospal M; Quenzer A; Peter S; Germer CT; Linnebacher M; Otto C
Neoplasia; 2017 Apr; 19(4):301-309. PubMed ID: 28284059
[TBL] [Abstract][Full Text] [Related]
29. Curcumin mediates chemosensitization to 5-fluorouracil through miRNA-induced suppression of epithelial-to-mesenchymal transition in chemoresistant colorectal cancer.
Toden S; Okugawa Y; Jascur T; Wodarz D; Komarova NL; Buhrmann C; Shakibaei M; Boland CR; Goel A
Carcinogenesis; 2015 Mar; 36(3):355-67. PubMed ID: 25653233
[TBL] [Abstract][Full Text] [Related]
30. Smad4 inactivation predicts for worse prognosis and response to fluorouracil-based treatment in colorectal cancer.
Kozak MM; von Eyben R; Pai J; Vossler SR; Limaye M; Jayachandran P; Anderson EM; Shaffer JL; Longacre T; Pai RK; Koong AC; Chang DT
J Clin Pathol; 2015 May; 68(5):341-5. PubMed ID: 25681512
[TBL] [Abstract][Full Text] [Related]
31. Predictors of survival and toxicity in patients on adjuvant therapy with 5-fluorouracil for colorectal cancer.
Gusella M; Frigo AC; Bolzonella C; Marinelli R; Barile C; Bononi A; Crepaldi G; Menon D; Stievano L; Toso S; Pasini F; Ferrazzi E; Padrini R
Br J Cancer; 2009 May; 100(10):1549-57. PubMed ID: 19384296
[TBL] [Abstract][Full Text] [Related]
32. Expression of CEACAM6 in resectable colorectal cancer: a factor of independent prognostic significance.
Jantscheff P; Terracciano L; Lowy A; Glatz-Krieger K; Grunert F; Micheel B; Brümmer J; Laffer U; Metzger U; Herrmann R; Rochlitz C
J Clin Oncol; 2003 Oct; 21(19):3638-46. PubMed ID: 14512395
[TBL] [Abstract][Full Text] [Related]
33. miR-20a targets BNIP2 and contributes chemotherapeutic resistance in colorectal adenocarcinoma SW480 and SW620 cell lines.
Chai H; Liu M; Tian R; Li X; Tang H
Acta Biochim Biophys Sin (Shanghai); 2011 Mar; 43(3):217-25. PubMed ID: 21242194
[TBL] [Abstract][Full Text] [Related]
34. Identification of Prognostic Biomarker Signatures and Candidate Drugs in Colorectal Cancer: Insights from Systems Biology Analysis.
Rahman MR; Islam T; Gov E; Turanli B; Gulfidan G; Shahjaman M; Banu NA; Mollah MNH; Arga KY; Moni MA
Medicina (Kaunas); 2019 Jan; 55(1):. PubMed ID: 30658502
[TBL] [Abstract][Full Text] [Related]
35. Validation of biomarkers associated with 5-fluorouracil and thymidylate synthase in colorectal cancer.
Xi Y; Formentini A; Nakajima G; Kornmann M; Ju J
Oncol Rep; 2008 Jan; 19(1):257-62. PubMed ID: 18097604
[TBL] [Abstract][Full Text] [Related]
36. Comprehensive Genetic Search to Clarify the Molecular Mechanism of Drug Resistance Identifies ASCL2-LEF1/TSPAN8 Axis in Colorectal Cancer.
Tanaka T; Kojima K; Yokota K; Tanaka Y; Ooizumi Y; Ishii S; Nishizawa N; Yokoi K; Ushiku H; Kikuchi M; Kojo K; Minatani N; Katoh H; Sato T; Nakamura T; Sawanobori M; Watanabe M; Yamashita K
Ann Surg Oncol; 2019 May; 26(5):1401-1411. PubMed ID: 30706227
[TBL] [Abstract][Full Text] [Related]
37. The colorectal cancer disease-specific transcriptome may facilitate the discovery of more biologically and clinically relevant information.
Allen WL; Jithesh PV; Oliver GR; Proutski I; Longley DB; Lenz HJ; Proutski V; Harkin P; Johnston PG
BMC Cancer; 2010 Dec; 10():687. PubMed ID: 21172019
[TBL] [Abstract][Full Text] [Related]
38. CEACAM1 and hollow spheroid formation modulate the chemosensitivity of colorectal cancer to 5-fluorouracil.
Yamamoto N; Yokoyama S; Ieda J; Mitani Y; Yamaguchi S; Takifuji K; Hotta T; Matsuda K; Watanabe T; Shively JE; Yamaue H
Cancer Chemother Pharmacol; 2015 Feb; 75(2):421-30. PubMed ID: 25547406
[TBL] [Abstract][Full Text] [Related]
39. Implementing prognostic and predictive biomarkers in CRC clinical trials.
Van Schaeybroeck S; Allen WL; Turkington RC; Johnston PG
Nat Rev Clin Oncol; 2011 Feb; 8(4):222-32. PubMed ID: 21321566
[TBL] [Abstract][Full Text] [Related]
40. Pharmacoproteomic characterisation of human colon and rectal cancer.
Frejno M; Zenezini Chiozzi R; Wilhelm M; Koch H; Zheng R; Klaeger S; Ruprecht B; Meng C; Kramer K; Jarzab A; Heinzlmeir S; Johnstone E; Domingo E; Kerr D; Jesinghaus M; Slotta-Huspenina J; Weichert W; Knapp S; Feller SM; Kuster B
Mol Syst Biol; 2017 Nov; 13(11):951. PubMed ID: 29101300
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
